Introduction
============

Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of non-Hodgkin's lymphomas with the characteristics of rare incidence, aggressive course, and poor survival.[@b1-ott-9-1795] PTCL, not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large cell lymphoma (ALCL) are the major PTCL subtypes in Asia, representing \~40% of cases.[@b2-ott-9-1795] The cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP) regimen is widely used as a first-line treatment for PTCL, but the outcomes are very poor with a 5-year overall survival (OS) rate of \~30%.[@b1-ott-9-1795]

With the increase in life expectancy, increasingly more patients with PTCL are \>60 years of age, and those patients always have one or more comorbidities such as diabetes or cerebrovascular disease, which not only influence the prognosis of the disease itself but may also affect the treatment choice.[@b3-ott-9-1795]--[@b5-ott-9-1795] Therefore, a single numeric score of comorbidity, based on the collection of several comorbidities, was a very useful and important method, which can reduce the number of candidate variables into a manageable set of proxy variables.[@b6-ott-9-1795],[@b7-ott-9-1795] The Charlson Comorbidity Index (CCI) is the most widely used comorbidity index.[@b5-ott-9-1795],[@b8-ott-9-1795]

An analysis to determine whether the CCI can predict the survival of elderly patients with PTCL has not yet been performed. It was reported that the CCI is a useful index to predict outcomes in nonhematologic[@b9-ott-9-1795]--[@b11-ott-9-1795] and hematologic malignancies.[@b12-ott-9-1795]--[@b14-ott-9-1795] Therefore, this retrospective study analyzed patients' clinical parameters and treatment outcomes to determine the impact of CCI on elderly patients with PTCL.

Materials and methods
=====================

Patient selection
-----------------

In this study, 56 patients aged \>60 years with newly diagnosed PTCL were recruited between April 2008 and August 2014. The last follow-up date was March 31, 2015. According to the World Health Organization classification,[@b15-ott-9-1795] the PTCL-NOS, ALCL, and AITL subtypes were included in this study. The study was approved by the Research Ethics Committee of Tianjin Cancer Hospital, People's Republic of China. Written informed consent was obtained from the patients prior to their participation.

Data collection
---------------

The patients' medical records were reviewed for their clinical, pathological, and treatment data. Each patient's history; performance status; blood routine; liver function; renal function; lactate dehydrogenase (LDH); computed tomography scans of the thorax, abdomen, and pelvic cavity; bone marrow aspiration and biopsy; and cognitive status were documented. International Prognostic Index (IPI) scores were based on age, Eastern Cooperative Oncology Group (ECOG) performance status, LDH concentrations, number of extranodal sites involved, and Ann Arbor stage. The treatment responses were classified as complete remission (CR), partial response (PR), stable disease (SD), or progressive disease (PD) according to the International Working Group criteria.[@b16-ott-9-1795] In this study, hemoglobin \<120 g/L was defined as low, LDH \>245 U/L was defined as high, and β-microglobulin (β2-MG) \>2.2 mg/L was defined as high. The CCI score of each patient was calculated according to their past and present medical history.[@b8-ott-9-1795],[@b17-ott-9-1795]

Statistical analysis
--------------------

A statistical analysis was performed using SPSS 19.0 soft-ware (SPSS Inc., Chicago, IL, USA). OS was calculated from the diagnosis until death from any cause, while progression-free survival (PFS) was calculated from the diagnosis until disease progression or death. The survival curve was calculated by the log-rank test. Multivariate analysis was performed using the Cox proportional hazards regression model. The GraphPad Prism software package was used to create the Kaplan--Meier estimate graphs. Values of *P*\<0.05 were considered statistically significant.

Results
=======

Patient characteristics
-----------------------

A total of 34 males (60.7%) and 22 females (39.3%) with a median age of 67 years (range: 60--80 years) were included in this study. With regard to histological subtypes, 41 (73.2%) patients had PTCL-NOS, nine (16.1%) had AITL, and six (10.7%) had ALCL. All of the patients were divided into the low CCI (score 0 or 1) and high CCI (score ≥2) groups. Thirteen patients were included in the high CCI group. The patients' clinical parameters and histological features are summarized in [Table 1](#t1-ott-9-1795){ref-type="table"}.

Twenty-eight (50%) patients had at least one comorbidity, the most common of which were diabetes and cerebrovascular disease ([Table 2](#t2-ott-9-1795){ref-type="table"}). Most patients were treated with CHOP or CHOP-like regimen as the first-line treatment, while six patients were treated with modified cyclophosphamide, doxorubicin, vincristine, and dexamethasone (HyperCVAD) and five were treated with another regimen. Thirty-four patients (60.7%) achieved CR or PR at the end of the treatment, while 22 patients (39.3%) had SD or PD.

Prognostic factor analysis
--------------------------

Each patient's medical records were retrospectively reviewed. The patients were divided into two subgroups according to age (≤70 vs \>70 years), sex (male vs female), ECOG score (0--1 vs 2--4), hemoglobin (normal vs low), B symptoms (present vs absent), Ann Arbor stage (I--II vs III--IV), β2-MG (normal vs elevated), bone marrow involvement (positive vs negative), LDH concentrations (normal vs elevated), IPI (1--2 vs 3--5), and CCI (0--1 vs ≤2).

Univariate analysis showed that an ECOG score of 2--4, the presence of B symptoms, an IPI of 3--5, and a CCI ≥2 were significantly associated with worse OS, while the presence of B symptoms, an IPI of 3--5, and a CCI ≥2 were associated with shortened PFS. Multivariate analysis indicated that a high CCI and a high IPI were poor independent prognostic factors for patients with PTCL ([Tables 3](#t3-ott-9-1795){ref-type="table"} and [4](#t4-ott-9-1795){ref-type="table"}). OS and PFS in the high CCI group were significantly shorter than those in the low CCI group (*P*=0.0085 and *P*=0.0028, respectively; [Figure 1](#f1-ott-9-1795){ref-type="fig"}).

Discussion
==========

PTCL encompasses a subset of rare and usually aggressive T-cell diseases that account for \~12% of cases of non-Hodgkin lymphomas in Western countries.[@b18-ott-9-1795] However, in Asia, the incidence was higher, \>20%.[@b19-ott-9-1795],[@b20-ott-9-1795] Due to its rarity and lack of standardized treatment strategies, its prognosis remains very poor.

The CCI is the most commonly applied comorbidity score system, and a high CCI represents shortened survival.[@b11-ott-9-1795],[@b21-ott-9-1795] It had been shown that the comorbidity can be regarded as an independent risk factor in several solid and hematological malignancies.[@b10-ott-9-1795],[@b22-ott-9-1795],[@b23-ott-9-1795] Studies on the impact of comorbidity on survival in B-cell non-Hodgkin lymphoma revealed that a high CCI was associated with poor OS.[@b13-ott-9-1795],[@b24-ott-9-1795],[@b25-ott-9-1795]

Until now, there have been no data on the ability of the CCI to predict survival in elderly patients with PTCL in a Chinese population. The purpose of this study was to assess comorbidity to evaluate survival among patients with PTCL treated with CHOP or CHOP-like regimen. Univariate analysis showed that the presence of B symptoms, an IPI of 3--5, and a CCI ≥2 were significantly associated with shortened OS and PFS. Multivariate analysis findings suggested that a high CCI was an independent poor risk factor for elderly patients with PTCL.

Conclusion
==========

Comorbidity was considered a poor independent prognostic factor for shortened OS and PFS in patients with PTCL treated with CHOP or CHOP-like regimen. Further studies with larger samples are warranted to confirm our findings.
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###### 

Clinical characteristics of patients with PTCL

  Characteristic             No of patients (%)
  -------------------------- --------------------
  Sex                        
   Male                      34 (60.7)
   Female                    22 (39.3)
  Age (years)                
   ≤70                       38 (67.9)
   \>70                      18 (32.1)
  Performance status         
   ECOG 0--1                 32 (57.1)
   ECOG 2--4                 24 (42.9)
  Pathological type          
   PTCL-NOS                  41 (73.2)
   AITL                      9 (16.1)
   ALCL                      6 (10.7)
  LDH                        
   Normal                    21 (37.5)
   Elevated                  35 (62.5)
  Hemoglobin                 
   Normal                    43 (76.8)
   Low                       13 (23.2)
  B symptoms                 
   Present                   23 (41.1)
   Absent                    33 (58.9)
  β2-MG                      
   Normal                    34 (60.7)
   Elevated                  22 (39.3)
  Bone marrow involvement    
   Yes                       4 (7.0)
   No                        52 (93.0)
  Ann Arbor stage            
   I/II                      17 (30.4)
   III/IV                    39 (69.6)
  IPI                        
   1--2                      20 (35.7)
   3--5                      36 (64.3)
  CCI                        
   0                         28 (50.0)
   1                         15 (26.8)
   2                         6 (10.7)
   \>2                       7 (12.5)
  Treatment                  
   CHOP/CHOP-like regimen    45 (80.4)
   Regimen other than CHOP   11 (19.6)
  Therapeutic evaluation     
   CR/PR                     34 (60.7)
   SD/PD                     22 (39.3)

**Abbreviations:** PTCL-NOS, peripheral T-cell lymphoma, not otherwise specified; ALCL, anaplastic large cell lymphoma; AITL, angioimmunoblastic T-cell lymphoma; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; β2-MG, β-microglobulin; CHOP, combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone; IPI, International Prognostic Index; CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease; CCI, Charlson Comorbidity Index.

###### 

Charlson Comorbidity Index of patients with PTCL

  Characteristic                                        Score   No of patients
  ----------------------------------------------------- ------- ----------------
  Myocardial infarction                                 1       2
  Congestive heart failure                              1       1
  Peripheral vascular disease                           1       1
  Cerebrovascular disease (except                       1       7
  hemiplegia)                                                   
  Dementia                                              1       1
  Chronic pulmonary disease                             1       1
  Connective tissue disease                             1       2
  Ulcer disease                                         1       3
  Mild liver disease                                    1       1
  Diabetes without complications                        1       12
  Diabetes with end-organ damage                        2       1
  Hemiplegia                                            2       1
  Moderate or severe renal disease                      2       0
  Second solid tumor (nonmetastatic)                    2       0
  Leukemia                                              2       0
  Lymphoma[\*](#tfn2-ott-9-1795){ref-type="table-fn"}   2       0
  Moderate or severe liver disease                      3       1
  Second metastatic solid tumor                         6       0
  Acquired immunodeficiency syndrome                    6       0

**Note:**

Excluded from analysis.

**Abbreviation:** PTCL, peripheral T-cell lymphoma.

###### 

Univariate and multivariate analyses of the prognostic risk factors for overall survival in PTCL

  Variable                                  Univariate analysis   Multivariate analysis                       
  ----------------------------------------- --------------------- ----------------------- ------------------- -------
  ECOG (0--1 vs 2--4)                       1.84 (0.25--3.56)     0.031                   1.38 (0.82--3.15)   0.635
  Ann Arbor stage (I--II vs III--IV)        1.24 (1.35--4.67)     0.134                                       
  B symptoms (absent vs present)            2.57 (0.45--7.89)     0.032                   0.82 (0.34--2.18)   0.514
  β2-MG (normal vs elevated)                0.73 (0.46--3.24)     0.572                                       
  LDH (normal vs elevated)                  0.59 (0.14--2.31)     0.786                                       
  IPI (1--2 vs 3--5)                        4.12 (1.59--6.45)     0.028                   4.12 (1.36--6.72)   0.01
  CCI (0--1 vs ≥2)                          3.24 (0.73--6.45)     0.019                   3.56 (0.82--4.51)   0.006
  Therapeutic evaluation (CR/PR vs SD/PD)   2.38 (0.62--6.42)     0.673                                       

**Abbreviations:** PTCL, peripheral T-cell lymphoma; HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; β2-MG, β-microglobulin; LDH, lactate dehydrogenase; IPI, International Prognostic Index; CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease; CCI, Charlson Comorbidity Index Score.

###### 

Univariate and multivariate analyses of the prognostic risk factors for progression-free survival in PTCL

  Variable                                  Univariate analysis   Multivariate analysis                       
  ----------------------------------------- --------------------- ----------------------- ------------------- -------
  ECOG (0--1 vs 2--4)                       1.32 (1.02--4.32)     0.071                                       
  Ann Arbor stage (I--II vs III--IV)        1.48 (0.58--3.64)     0.233                                       
  B symptoms (absent vs present)            2.72 (1.63--6.42)     0.045                   1.46 (0.68--2.89)   0.472
  β2-MG (normal vs elevated)                1.29 (0.71--3.87)     0.592                                       
  LDH (normal vs elevated)                  0.78 (0.43--3.20)     0.134                                       
  IPI (1--2 vs 3--5)                        2.94 (1.52--5.61)     0.032                   3.01 (0.98--5.61)   0.017
  CCI (0--1 vs ≥2)                          2.39 (0.54--3.72)     0.016                   2.99 (1.14--4.58)   0.008
  Therapeutic evaluation (CR/PR vs SD/PD)   2.69 (0.35--6.27)     0.187                                       

**Abbreviations:** PTCL, peripheral T-cell lymphoma; HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; β2-MG, β-microglobulin; LDH, lactate dehydrogenase; IPI, International Prognostic Index; CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease; CCI, Charlson Comorbidity Index Score.
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